TY - JOUR AB - Cancer/testis (CT) antigens are considered target molecules for cancer immunotherapy. To identify novel CT antigens, immunoscreening of a testicular cDNA library was performed using serum obtained from a colon cancer patient who was immunized with a new dendritic cell vaccine. We isolated 64 positive cDNA clones comprised of 40 different genes, designated KP-CoT-1 through KP-CoT-40. Three of these putative antigens, including KP-CoT-23 (CCDC83), had testis-specific expression profiles in the Unigene database. RT-PCR analysis showed that the expression of 2 KP-Cot-23 variants was restricted to the testis in normal adult tissues. In addition, KP-CoT-23 variants were frequently expressed in a variety of tumors and cancer cell lines, including colon cancer. A serological western blot assay showed IgG antibodies to the KP-CoT-23 protein in 26 of 37 colon cancer patients and in 4 of 21 healthy patients. These data suggest that KP-CoT-23 is a novel CT antigen that may be useful for the diagnosis and immunotherapy of cancer. AD - Department of Biochemistry, School of Medicine, Pusan National University, Yangsan‑si, Gyeongsangnam‑do 626-770, Republic of Korea Department of Pathology, School of Medicine, Pusan National University, Yangsan‑si, Gyeongsangnam‑do 626-770, Republic of Korea Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA AU - Song,Myung-Ha AU - Ha,Jin-Mok AU - Shin,Dong-Hoon AU - Lee,Chang‑Hun  AU - Old,Lloyd AU - Lee,Sang-Yull DA - 2012/11/01 DO - 10.3892/ijo.2012.1601 EP - 1826 IS - 5 JO - Int J Oncol KW - SEREX cancer/testis antigen colon cancer KP‑CoT‑23 CCDC83 PY - 2012 SN - 1019-6439 1791-2423 SP - 1820 ST - KP-CoT-23 (CCDC83) is a novel immunogenic cancer/testis antigen in colon cancer T2 - International Journal of Oncology TI - KP-CoT-23 (CCDC83) is a novel immunogenic cancer/testis antigen in colon cancer UR - https://doi.org/10.3892/ijo.2012.1601 VL - 41 ER -